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ABSTRACT  
A simple, sensitive, rapid and precise high performance thin layer chromatographic 
method has been developed and validated for the estimation of Tolperisone 
hydrochloride in bulk and pharmaceutical dosage form. The stationary phase used 
was silica gel precoated aluminum plate 60F254 plates. The mobile phase used was a 
mixture of chloroform:acetone:toluene (6:2:2, v/v/v). The detection of spots was 
carried out at 265 nm. The method was validated in terms of specificity, linearity, 
precision and accuracy. The calibration curve was found to be linear between 50-
600 ng/band. The developed method was subjected for forced degradation studies 
like acid, alkali, peroxide and thermal stress conditions were performed as per ICH 
guidelines. The proposed method was suitable for routine quality control analysis of 
Tolperisone hydrochloride in bulk and pharmaceutical formulation.  
INTRODUCTION
Tolperisone hydrochloride (Fig. 1) is a skeletal 
muscle relaxant, acts at the level of spinal cord by 
blocking sodium channels and calcium channels [1-2]. 
Chemically it is 2-methyl-1-(4-methylphenyl)-3-(1-
piperidinyl)-1-propanone hydrochloride [3]. 
Tolperisone hydrochloride exerts its spinal reflex 
inhibitory action predominantly via pre-synaptic 
inhibition of the transmitter release from the 
primary afferent endings via combined action on 
voltage-gated sodium and calcium channels [4]. 
Tolperisone hydrochloride increases the blood 
supply to skeletal muscle and antinociceptive 
activity against thermal stimulation that is likely to 
be attributed to its local anesthetic action [5]. 
Literature survey revealed that few HPTLC methods 
[6-7] were reported for the estimation of Tolperisone 
hydrochloride. Hence the objective of this method is 
to develop and validate a simple, precise and rapid 
HPTLC method in accordance with ICH guidelines [8-
9] for the estimation of Tolperisone hydrochloride in 
bulk sample and its pharmaceutical formulation. 
 EXPERIMENTAL 
Instrumentation  
To develop a high performance thin layer 
chromatographic method for quantitative 
determination of Tolperisone hydrochloride using 
computerized Camag HPTLC system (Camag, 
Muttenz, Switzerland) consisting of a Camag 100 
microlitre sample syringe (Hamilton, Bonded, 
Switzerland) on silica gel precoated aluminum plate 
60F254 plates, [20 m × 20cm width 200μm thickness; 
E. Merck, Darmstadt, Germany] using a Camag 
Linomat V (Switzerland) sample applicator. 
Densitometric scanning was performed using a 
Camag TLC scanner III in the reflectance 
absorbance mode at 265 nm and operated by CATS 
software (V 3.15, Camag). The source of radiation 
used was deuterium lamp emitting a continuous UV 
spectrum between 190 nm and 400 nm. A Camag 
glass twin-trough development chamber, different 
size pipettes, volumetric flasks, measuring 
cylinders, micro syringes and ruler were used. 
Chemicals and solvents  
The reference samples of Tolperisone 
hydrochloride was obtained as gift sample from 
Spectrum Pharma Research Solutions, Hyderabad, 
India. Commercially available tablet formulation 
claimed to contain 150 mg of Tolperisone 
hydrochloride was purchased from local market. 
Chloroform, acetone and toluene purchased from 
Merck Chemicals, Mumbai, India. 
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Preparation of standard solution  
Accurately weighed and transferred 50 mg of 
Tolperisone hydrochloride into a 100 mL clean dry 
volumetric flask, about 10 mL of diluent was added 
and volume was made upto the mark by using 
diluent. Further 1 mL of above stock solution was 
pipetted into100 mL volumetric flask and diluted 
upto the mark by adding diluent. From this 1 mL of 
the solution was pipettted into a 100 mL volumetric 
flask and made upto the mark with diluent. From 
this serial dilutions were prepared to construct the 
calibration curve. 
Preparation of sample solution 
Twenty tablets were accurately weighed and 
crushed into a fine powder in a mortar. An amount 
of powder equivalent to 150 mg of Tolperisone 
hydrochloride into 100 mL volumetric flask and 
about 50 mL of diluent was added. The mixture was 
sonicated for 20 min to dissolve and made volume 
upto the mark with diluent; then solution was 
filtered through 0.45 µm filter paper. Further 1 mL 
of solution was pipetted and transferred into100 
mL volumetric flask, made volume upto the mark by 
using diluent. From the above stock solution, 2 mL 
of the solution was pipetted into a 100 mL 
volumetric flask and made upto volume with mobile 
phase to yield concentration 300 ng/band of 
Tolperisone hydrochloride. 
Method  
TLC plates were prewashed and activation of plates 
was done in an oven at 500C for 5-10 min. The 
chromatographic conditions maintained were 
precoated silica gel 60F254 aluminum sheets (10x10 
cm) as stationary phase, chloroform:acetone: 
toluene (6:2:2, v/v/v) as mobile phase. The mobile 
phase was used as diluent, chamber and plate 
saturation time of 20 min, migration distance 
allowed was 72 mm, keeping the slit dimension at 
5x0.45 mm. A deuterium lamp provided the source 
of radiation. Ten microliters of standard solution of 
Tolperisone hydrochloride was spotted and 
developed at constant temperature. Wavelength 
was selected by scanning standard solution over 
200-400 nm wavelength. Tolperisone 
hydrochloride show maximum absorbance at 265 
nm in reflectance mode with Camag TLC Scanner 3 
using WinCATS software. 
Calibration curve  
Aliquot of 50, 100, 200, 300, 400, 500 and 600 
ng/band of standard solution of Tolperisone 
hydrochloride was applied on the TLC plate. TLC 
plate was dried, developed and analyzed 
photometrically as described earlier. The standard 
calibration curve was plotted using regression 
analysis with Microsoft excel. 
Validation of the method  
The developed method was validated in terms of 
specificity, linearity, system precision, method 
precision and intermediate precision, accuracy, 
limit of detection and limit of quantitation. 
STABILITY STUDIES  
Forced degradation studies were conducted 
indicating the stability of proposed method by 
subjecting the sample for acid degradation, alkali 
degradation, peroxide degradation and thermal 
degradation.    
Control sample  
Twenty tablets were accurately weighed and 
crushed in to a fine powder in a mortar. An amount 
of powder equivalent to 150 mg of Tolperisone 
hydrochloride into 100 mL volumetric flask and 50 
mL of diluent was added to it. The mixture was 
sonicated for 20 min to dissolve and made volume 
up to the mark with diluent; the solution was 
filtered through 0.45 µm filter paper. Further 1 mL 
of solution was transferred to 100 mL volumetric 
flask, made volume upto the mark by using diluent. 
From the above stock solution, 2 mL of the solution 
was pipetted into a 100 mL volumetric flask and 
made upto the mark with diluent.  
Acid degradation studies  
Twenty tablets were weighed and finely powdered. 
An accurately weighed portion of powder sample 
equivalent to 150 mg of Tolperisone hydrochloride 
was transferred to a 100 mL volumetric flask 
containing 50 mL of the diluent. The contents of the 
flask were sonicated for about 30 min for complete 
solubility of the drug with intermittent shaking at 
controlled temperature and the volume was made 
up to the mark by using diluent. From this 1 mL of 
the solution was pipetted into 100 mL volumetric 
flask and made volume upto the mark with diluent. 
Then 5 mL of 0.1N acid (Hydrochloric acid) was 
added, refluxed for 8 hours at 60°C, then cooled to 
room temperature, neutralized with 0.1N base 
(Sodium hydroxide) and diluted to volume with 
diluent. Then this mixture was filtered through 0.45 
µ membrane filter.  2 mL of the above filtered 
sample solution was pipetted into a 100 mL 
volumetric flask and diluted to volume with diluent.  
Alkali degradation studies  
Twenty tablets were weighed and finely powdered. 
An accurately weighed portion of powder sample 
equivalent to 150 mg of Tolperisone hydrochloride 
was transferred to a 100 mL volumetric flask 
containing 50 mL of the diluent. The contents of the 
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flask were sonicated for about 30 min for complete 
solubility of the drug with intermittent shaking at 
controlled temperature and the volume was made 
upto the mark by using diluent. From this 1 mL of 
the solution was pipetted into 100 mL volumetric 
flask and made volume upto the mark with diluent. 
Then 5 mL of 0.1N base (Sodium hydroxide) was 
added, refluxed for 8 hours at 60°C, then cooled to 
room temperature, neutralized with 0.1N acid 
(Hydrochloric acid) and diluted to volume with 
diluent. Then this mixture was filtered through 0.45 
µ membrane filter.  Pipetted 2.0 mL of the above 
filtered sample solution into a 100 mL volumetric 
flask and diluted to volume with diluent.  
Peroxide degradation studies  
Twenty tablets were weighed and finely powdered. 
An accurately weighed portion of powder sample 
equivalent to 150 mg of Tolperisone hydrochloride 
was transferred to a 100 mL volumetric flask 
containing 50 mL of the diluent. The contents of the 
flask were sonicated for about 30 min for complete 
solubility of the drug with intermittent shaking at 
controlled temperature volume was made upto the 
mark by using diluent. From this 1 mL of the 
solution was transferred into 100 mL volumetric 
flask and made volume upto the mark with diluent 
Then 2 mL of 3 % hydrogen peroxide was added, 
refluxed for 8 hours at 60°C, then cooled to room 
temperature and diluted to volume with diluent. 
Then this mixture was filtered through 0.45 µ 
membrane filter. 2.0 mL of the above filtered 
sample solution was pipetted into a 100 mL 
volumetric flask and diluted to volume with diluent.  
Thermal degradation studies  
Twenty tablets were weighed and finely powdered. 
The powder is exposed to heat at 105°C for about 8 
hours. An accurately weighed portion of powder 
sample equivalent to 150 mg of Tolperisone 
hydrochloride was transferred to a 100 mL 
volumetric flask containing 50 mL of the diluent. 
The contents of the flask were sonicated for about 
30 min for complete solubility of the drug with 
intermittent shaking at controlled temperature and 
then cooled the solution to room temperature and 
volume made up with further quantity of diluent. 
Then this mixture was filtered through 0.45 µ 
membrane filter. 3.3 mL of the above filtered 
sample solution was pipetted into a 100 mL 
volumetric flask and diluted to volume with diluent.  
 
.                  Fig. 1: Chemical structure of Tolperisone hydrochloride 
 
Fig. 2: Calibraton curve of Tolperisone hydrochloride 
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Fig. 3: Typical densitogram of Tolperisone hydrochloride 
 
Fig. 4: Densitogram of acid degradation showing Tolperisone hydrochloride 
 
Fig. 5: Densitogram of alkali degradation showing Tolperisone hydrochloride 
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Fig. 6: Densitogram of peroxide degradation showing Tolperisone hydrochloride 
 
Fig. 7: Densitogram of thermal degradation showing Tolperisone hydrochloride 
Table 1: Optimized chromatographic conditions of Tolperisone hydrochloride 
Parameter Condition 
 Mobile phase Chlororfrom:acetone:toluene (6:2:2, v/v/v) 
Diluent Mobile phase 
Stationary phase Silica gel precoated aluminum plate 60F254 plates 
Saturation time  20 min 
Wave length 265 nm 
Sample volume 10 µL 
Rf 0.41 
                                     Table 2: Linearity study of Tolperisone hydrochloride 
Concentration (ng/band) Mean peak area 
50 1257.85 
100 1826.93 
200 2778.24 
300 3685.82 
400 4509.86 
500 5575.69 
600 6447.2 
Slope 9.345 
Intercept 855.6 
Correlation Coefficient 0.999 
Table 3: Validation parameters of Tolperisone hydrochloride 
Parameters Values 
Linearity range (ng/band) 50-600 
Limit of detection (LOD) 10 ng/band 
Limit of quantitation (LOQ) 30 ng/band 
Precision (% RSD) 
System precision (n=6) 
Method precision (n=6) 
Intermediate precision (n=6)  
 
1.3 
0.78 
0.33 
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Table 4: Recovery results of Tolperisone hydrochloride 
Level 
Concentration 
added (ng/band) 
Concentration  
found (ng/band) 
% Recovery Mean recovery 
50% 150 148.9 99.26%  
99.64% 100% 300 299.44 99.81% 
150% 450 449.41 99.87% 
*Each value is a mean ± standard deviation of three determinations.    
Table 5: Degradation studies of Tolperisone hydrochloride 
Stress conditions Degradation time % Assay % Degradation 
Control 8 hours 100.0 - 
Acidic 8 hours 97.6 2.4 
Alkali 8 hours 95.23 4.77 
Peroxide 8 hours 98.4 1.6 
Thermal 8 hours 98.2 1.8 
RESULTS AND DISCUSSION 
For HPTLC, silica gel precoated aluminum plates 
60F254 was chosen as the stationary phase for the 
separation and determination of Tolperisone 
hydrochloride. Mixture of commonly used solvents 
like butane:ethyl acetate, chloroform:butanol: 
toluene combinations were tested as mobile phase. 
The choice of the optimum composition was based 
on the chromatographic response factor, a good 
peak shape with minimum tailing. A mixture of 
chloroform:acetone:toluene (6:2:2, v/v/v) was 
proved to be the most suitable of all the 
combinations since the densitogram  peak obtained 
was well defined peaks are measured at 265 nm, 
better resolved. The results of optimized 
chromatographic conditions of Tolperisone 
hydrochloride were shown in Table 1.  
The specificity of method was performed by 
comparing the densitograms of blank, standard and 
sample. The absence of additional peaks in the 
densitogram indicates non-interference of the 
commonly used excipients in the tablets and hence 
the method was specific. The linearity was found 
50-600 ng/band of Tolperisone hydrochloride. The 
regression equation of the linearity curve between 
concentrations of Tolperisone hydrochloride over 
its peak areas were found to be Y=9.345X+855.6 
(where Y is the peak area and X is the concentration 
of Tolperisone hydrochloride in ng/band) and the 
correlation coefficient was 0.999. The linearity 
curve of Tolperisone hydrochloride was shown in 
Fig. 2. The linearity results were furnished in Table 
2.    
To study the system precision, six replicate 
standard solutions of Tolperisone hydrochloride 
was injected. The %RSD was calculated and it was 
found to be 1.3 of Tolperisone hydrochloride, which 
are well within the acceptable criteria of not more 
than 2.0. The method precision study was carried 
out on six preparations from the same tablet 
samples of Tolperisone hydrochloride percent 
amount of both were calculated. The %RSD of the 
assay result of six preparations in method precision 
study was found to be 0.78. The intermediate 
precision study was carried out by different 
analysts; from the same tablet of Tolperisone 
hydrochloride in the percent amount of Tolperisone 
hydrochloride was calculated. The %RSD of the 
assay result of six preparations in intermediate 
precision study was 0.33. The lower %RSD values 
reveals that the method quite precise. 
The limit of detection and limit of quantitation for 
Tolperiosne hydrochloride was found to be 10 
ng/band and 30 ng/band. The lowest values of LOD 
and LOQ as obtained by the proposed method 
indicate that the method was sensitive. The method 
validation parameters were shown in Table 3.  
The accuracy of the method was determined by 
recovery studies. The percent recoveries of the drug 
solutions were studied at three different 
concentration levels. The percent recovery and 
%RSD at each level was calculated. Satisfactory 
recoveries ranging from 99.26 to 99.87% of 
Tolperisone hydrochloride was obtained by the 
proposed method. The percent individual recovery 
and the %mean recovery at each level were within 
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the acceptable limits.  This indicates that the 
method was accurate. The recovery studies results 
are furnished in Table 4. The Rf value of the 
Tolperisone hydrochloride was found to be 0.41. 
The densitogram of Tolperisone hydrochloride was 
shown in Fig. 3.  
HPTLC studies of Tolperisone hydrochloride under 
different stress conditions indicated the following 
degradation behavior. In acid degradation, the % 
degradation was 2.4%. In alkali degradation, the % 
degradation was 4.77%. In peroxide degradation, 
the % degradation was 1.6%. In thermal 
degradation, the % degradation was 1.8%. The 
results of degradation studies  are given in Table 5. 
The typical chromatograms of degradation behavior 
of Tolperisone hydrochloride in different stress 
conditions are shown in Fig. 4 to Fig. 7.  
CONCLUSION 
The developed HPTLC method for the estimation of 
Tolperisone hydrochloride is simple, specific, 
precise, accurate and reproducible. The amounts 
found in formulations are well agreed with label 
claim. The proposed method can be applied to 
routine analysis in quality control laboratories for 
the estimation of Tolperisone hydrochloride in bulk 
and in pharmaceutical formulation.      
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